Myelofibrosis screening: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
*There is insufficient evidence to recommend routine screening for myelofibrosis. | *There is insufficient evidence to recommend routine screening for myelofibrosis. | ||
*Blood cell counts can be determined and monitored for any irregularity which can then further warrant a bone marrow biopsy. | *Blood cell counts can be determined and monitored for any irregularity which can then further warrant a bone marrow biopsy. | ||
*According to 2008 WHO classification of myeloproliferative neoplasms, JAK2V617F is the most prevalent mutation with approximately 60% of the primary myelofibrosis (PMF) patients carrying this muatation. This trend is followed in frequency by the mutations in | *According to 2008 WHO classification of myeloproliferative neoplasms, JAK2V617F is the most prevalent mutation with approximately 60% of the primary myelofibrosis (PMF) patients carrying this muatation. This trend is followed in frequency by the mutations in myeloproliferative leukemia virus (MPL) and calreticulin (CALR) genes.<ref name="pmid29426921">{{cite journal |vauthors=Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A |title=The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion |journal=Blood Cancer J |volume=8 |issue=2 |pages=15 |date=February 2018 |pmid=29426921 |pmc=5807384 |doi=10.1038/s41408-018-0054-y |url=}}</ref><ref name="pmid15858187">{{cite journal |vauthors=Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC |title=A gain-of-function mutation of JAK2 in myeloproliferative disorders |journal=N. Engl. J. Med. |volume=352 |issue=17 |pages=1779–90 |date=April 2005 |pmid=15858187 |doi=10.1056/NEJMoa051113 |url=}}</ref> | ||
myeloproliferative leukemia virus (MPL) and calreticulin (CALR).<ref name="pmid29426921">{{cite journal |vauthors=Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A |title=The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion |journal=Blood Cancer J |volume=8 |issue=2 |pages=15 |date=February 2018 |pmid=29426921 |pmc=5807384 |doi=10.1038/s41408-018-0054-y |url=}}</ref> | |||
*Patients can be screened for the above mentioned mutations based on this data. | *Patients can be screened for the above mentioned mutations based on this data. | ||
Revision as of 15:50, 21 November 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis screening On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis screening |
|
Risk calculators and risk factors for Myelofibrosis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
There is insufficient evidence to recommend routine screening for myelofibrosis and there is no screening test currently available for the disease. Routine blood work can be used to check the blood cell counts which can further warrant a bone marrow biopsy.
Screening
- There is insufficient evidence to recommend routine screening for myelofibrosis.
- Blood cell counts can be determined and monitored for any irregularity which can then further warrant a bone marrow biopsy.
- According to 2008 WHO classification of myeloproliferative neoplasms, JAK2V617F is the most prevalent mutation with approximately 60% of the primary myelofibrosis (PMF) patients carrying this muatation. This trend is followed in frequency by the mutations in myeloproliferative leukemia virus (MPL) and calreticulin (CALR) genes.[1][2]
- Patients can be screened for the above mentioned mutations based on this data.
References
- ↑ Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (February 2018). "The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion". Blood Cancer J. 8 (2): 15. doi:10.1038/s41408-018-0054-y. PMC 5807384. PMID 29426921.
- ↑ Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (April 2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N. Engl. J. Med. 352 (17): 1779–90. doi:10.1056/NEJMoa051113. PMID 15858187.